Funding provided by TerSera Therapeutics LLC. Content independently developed by OncLive.
Ovarian Suppression with GnRH Agonists Can Aid Fertility Preservation in Breast Cancer
Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.
Dr. Kroener on Utilizing Embryo Cryopreservation in Breast Cancer
Lindsay L. Kroener, MD, discusses fertility preservation in patients with breast cancer.
Dr. Lambertini on the Effect of GnRH Agonists on Ovarian Function in Breast Cancer
Matteo Lambertini, MD, discusses how GnRH agonists work to preserve ovarian function in premenopausal patients with breast cancer.
Dr. Khan on the Ideal Patients for GnRH Agonists in Breast Cancer
Zaraq Khan, MBBS, discusses which patients with breast cancer would be ideal candidates to receive treatment with a GnRH agonist for ovarian protection.
Dr. Ruddy on the Use of GnRH Agonists in Breast Cancer
Kathryn Ruddy, MD, discusses the use of GnRH agonists in breast cancer.
Dr. Partridge on the Utilization of GnRH Agonists in Breast Cancer
Ann H. Partridge, MD, MPH, discusses the utilization of GnRH agonists to preserve ovarian function in premenopausal patients with breast cancer.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.